InvestSMART

Acrux Limited (ASX:ACR)

ALERT: Price-sensitive ASX Announcement for ACR
Current share price for ACR : $0.012 0.002 (15%)+
Announcement
Release
28 May 2026 9:04AM
Price at Release
$0.010
Full Release
download
Summary
Acrux Limited announced an amended licensing agreement with Gedeon Richter Plc for the distribution of Lenzetto, a transdermal Estradiol spray, in the Australian market. This deal, valued at up to AUD 5.4 million in milestone payments, aims to address the shortage of Menopause Hormone Therapy products in Australia. Lenzetto, already marketed globally, will be distributed in Australia using Acrux's innovative Patchless Patch technology. The agreement underscores Acrux's commitment to enhancing women's healthcare and securing financial growth through strategic partnerships.
Key Points
  • Acrux licenses Lenzetto for the Australian market for AUD 5.4 million.
  • The agreement addresses a shortage of Menopause Hormone Therapy products in Australia.
  • Acrux will receive milestone payments from Gedeon Richter Plc, totaling up to AUD 5.4 million.
  • Lenzetto, a transdermal Estradiol spray, is already marketed in over 40 countries.
  • The product uses Acrux's Patchless Patch delivery technology.
  • John Warmbrunn, CEO of Acrux, highlights the financial benefits and market expansion.
  • Felicia Colagrande, Product Development Director, emphasizes ease of use for Australian women.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.